8.25 USD
+0.19 (+2.36%)
8.45 USD
+0.2 (+2.42%)
Overall LFCR gets a fundamental rating of 2 out of 10. We evaluated LFCR against 57 industry peers in the Life Sciences Tools & Services industry. LFCR has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LFCR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LFCR has reported negative net income.
In the past year LFCR had a positive cash flow from operations.
In the past 5 years LFCR reported 4 times negative net income.
In the past 5 years LFCR reported 4 times negative operating cash flow.
1.2 Ratios
LFCR has a Return On Assets of -16.60%. This is in the lower half of the industry: LFCR underperforms 61.40% of its industry peers.
Looking at the Return On Equity, with a value of -106.13%, LFCR is doing worse than 78.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.6% | ||
| ROE | -106.13% | ||
| ROIC | N/A |
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LFCR has a Gross Margin of 31.57%. This is in the lower half of the industry: LFCR underperforms 66.67% of its industry peers.
In the last couple of years the Gross Margin of LFCR has grown nicely.
LFCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
2. Health
2.1 Basic Checks
LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFCR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFCR has been increased compared to 5 years ago.
Compared to 1 year ago, LFCR has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.45, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
LFCR has a Altman-Z score of 0.45. This is in the lower half of the industry: LFCR underperforms 73.68% of its industry peers.
LFCR has a Debt/Equity ratio of 3.67. This is a high value indicating a heavy dependency on external financing.
LFCR's Debt to Equity ratio of 3.67 is on the low side compared to the rest of the industry. LFCR is outperformed by 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.67 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.45 |
ROIC/WACCN/A
WACC9.59%
2.3 Liquidity
A Current Ratio of 2.80 indicates that LFCR has no problem at all paying its short term obligations.
With a Current ratio value of 2.80, LFCR perfoms like the industry average, outperforming 52.63% of the companies in the same industry.
A Quick Ratio of 1.67 indicates that LFCR should not have too much problems paying its short term obligations.
LFCR's Quick ratio of 1.67 is in line compared to the rest of the industry. LFCR outperforms 42.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.8 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
The earnings per share for LFCR have decreased strongly by -2114.69% in the last year.
Looking at the last year, LFCR shows a small growth in Revenue. The Revenue has grown by 5.31% in the last year.
Measured over the past years, LFCR shows a decrease in Revenue. The Revenue has been decreasing by -4.25% on average per year.
EPS 1Y (TTM)-2114.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
Revenue 1Y (TTM)5.31%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%
3.2 Future
Based on estimates for the next years, LFCR will show a very strong growth in Earnings Per Share. The EPS will grow by 23.41% on average per year.
Based on estimates for the next years, LFCR will show a very strong growth in Revenue. The Revenue will grow by 21.24% on average per year.
EPS Next Y36.35%
EPS Next 2Y22.31%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue Next Year1.62%
Revenue Next 2Y6.45%
Revenue Next 3Y8.7%
Revenue Next 5Y21.24%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LFCR. In the last year negative earnings were reported.
Also next year LFCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
LFCR's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 76.12 |
4.3 Compensation for Growth
A more expensive valuation may be justified as LFCR's earnings are expected to grow with 23.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.31%
EPS Next 3Y23.41%
5. Dividend
5.1 Amount
LFCR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
8.25
+0.19 (+2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners74.82%
Inst Owner ChangeN/A
Ins Owners1.78%
Ins Owner Change6.55%
Market Cap309.13M
Revenue(TTM)135.27M
Net Income(TTM)-39.04M
Analysts78.18
Price TargetN/A
Short Float %7.38%
Short Ratio17.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.4%
Min EPS beat(2)-7.29%
Max EPS beat(2)38.08%
EPS beat(4)2
Avg EPS beat(4)-40.23%
Min EPS beat(4)-207.19%
Max EPS beat(4)38.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.4%
Min Revenue beat(2)1.03%
Max Revenue beat(2)5.77%
Revenue beat(4)4
Avg Revenue beat(4)4.46%
Min Revenue beat(4)1.03%
Max Revenue beat(4)7.32%
Revenue beat(8)6
Avg Revenue beat(8)3.19%
Revenue beat(12)7
Avg Revenue beat(12)-4.87%
Revenue beat(16)8
Avg Revenue beat(16)-9.71%
PT rev (1m)-12.5%
PT rev (3m)-12.5%
EPS NQ rev (1m)-7.04%
EPS NQ rev (3m)-15.15%
EPS NY rev (1m)-9.06%
EPS NY rev (3m)-9.31%
Revenue NQ rev (1m)-1.74%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)-1.84%
Revenue NY rev (3m)-1.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.29 | ||
| P/FCF | N/A | ||
| P/OCF | 140.58 | ||
| P/B | 8.4 | ||
| P/tB | 16.53 | ||
| EV/EBITDA | 76.12 |
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0.06
OCFY0.71%
SpS3.61
BVpS0.98
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.6% | ||
| ROE | -106.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.57% | ||
| FCFM | N/A |
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
F-Score4
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.67 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 24.11 | ||
| Cap/Depr | 146.73% | ||
| Cap/Sales | 8.69% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 39.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.8 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 0.45 |
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)177.04%
Cap/Depr(5y)161.61%
Cap/Sales(3y)15.06%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2114.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
EPS Next Y36.35%
EPS Next 2Y22.31%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue 1Y (TTM)5.31%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%
Revenue Next Year1.62%
Revenue Next 2Y6.45%
Revenue Next 3Y8.7%
Revenue Next 5Y21.24%
EBIT growth 1Y60.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year688.24%
EBIT Next 3Y120.25%
EBIT Next 5YN/A
FCF growth 1Y80.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.07%
OCF growth 3YN/A
OCF growth 5YN/A
LIFECORE BIOMEDICAL INC / LFCR FAQ
What is the fundamental rating for LFCR stock?
ChartMill assigns a fundamental rating of 2 / 10 to LFCR.
What is the valuation status of LIFECORE BIOMEDICAL INC (LFCR) stock?
ChartMill assigns a valuation rating of 1 / 10 to LIFECORE BIOMEDICAL INC (LFCR). This can be considered as Overvalued.
Can you provide the profitability details for LIFECORE BIOMEDICAL INC?
LIFECORE BIOMEDICAL INC (LFCR) has a profitability rating of 1 / 10.
What is the expected EPS growth for LIFECORE BIOMEDICAL INC (LFCR) stock?
The Earnings per Share (EPS) of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 36.35% in the next year.